QNCX, US22053A1079

Quince Therapeutics stock wins approval for major share issuance

Published on 10/07/2026 at 02:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Quince Therapeutics stock secured approval for an issuance exceeding 20 percent of outstanding shares on October 6, 2026. The vote also raised authorized shares to 275 million.

QNCX, US22053A1079, Illustration mit AI erstellt.

Quince Therapeutics stock (ISIN US22053A1079) was trading at USD 28.150 on Nasdaq on October 6, 2026, while a shareholder vote approved an issuance representing more than 20 percent of outstanding common stock. The decision gives the biotechnology company broader financing capacity, but it also puts dilution and potential control changes at the center of the QNCX story.

Share issuance clears the vote

According to StockTitan on October 6, 2026, shareholders approved the conversion of Series C preferred stock, related warrants and options tied to Orphai Therapeutics. The approved issuance may represent more than 20 percent of outstanding shares and may contribute to a change of control together with management and board changes.

The same filing also records approval of a private-placement issuance and a charter amendment. Authorized common shares increase from 250,000,000 to 275,000,000, a 10 percent expansion in the authorized share count. The company also received approval for its 2026 equity incentive plan and employee stock purchase plan.

Vote shows concentrated ownership

Of 1,017,063 shares outstanding on the record date, 611,465 shares were present or represented by proxy, according to StockTitan. That represents 60.1 percent of the outstanding shares and shows how a relatively small absolute share base can produce material changes in ownership and voting power.

Quince Therapeutics is developing LAM-001 for pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome and sarcoidosis-associated pulmonary hypertension. Its investor-relations page identifies a completed Phase 2a study, an ongoing Phase 2 study in BOS and a Phase 2b study in PH-ILD.

Consensus stays far above price

Investing.com listed a Strong Buy consensus from 8 analysts, with 7 Buy ratings, 1 Hold rating and no Sell ratings. The average 12-month price target was USD 75.429, with a high of USD 98 and a low of USD 65. The average target lies 167.96 percent above the USD 28.150 price.

For the latest reported quarter, Q2 2026, Quince posted adjusted or reported EPS of USD -12.31 versus an estimated USD -18.2376, while revenue was USD 0.00, according to Fintel. The result beat the published EPS estimate, but the absence of revenue leaves the pipeline and financing structure as the key valuation variables.

QNCX trades near its yearly floor

QNCX was trading at USD 28.150 on Nasdaq on October 6, 2026, up 0.18 percent from the prior close of USD 28.100. Its session range was USD 27.005 to USD 28.150, while the 52-week range extended from USD 3.660 to USD 909.980 and market capitalization stood at USD 28.6 million.